Global Left Ventricular Dysfunction Drug Market

Left Ventricular Dysfunction Drug Comprehensive Study by Type (BAY-1142524, CAP-1002, Carvedilol CR, CTX-101, Omecamtiv Mecarbil, Others), Application (Hospital, Clinic, Others), Drug Type (Prescription Only, Over the Counter), End Users (Kids, Adults) Players and Region - Global Market Outlook to 2030

Left Ventricular Dysfunction Drug Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Left Ventricular Dysfunction Drug
Left ventricular dysfunction (LVD) produces many changes in the structure and function of the heart through a variety of mechanisms. It constitutes a common pathway for a host of cardiac disorders. Heart failure is more prevalent and has a higher incidence in the elderly population. Approximately 5.7 million people in the United States have diagnosed with heart failure every year.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States and European Players will contribute the maximum growth to Global Left Ventricular Dysfunction Drug market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bayer AG (Germany), Innopharmax Inc (Taiwan), Mesoblast Ltd (Australia), Novartis AG (Switzerland), Quantum Genomics SA (France), TiGenix NV (Belgium), Armaron Bio Pty Ltd. (Australia), Takeda Pharmaceutical Co Ltd (Japan), Viscofan BioEngineering (Germany) and GlaxoSmithKline (Germany) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Left Ventricular Dysfunction Drug market by Type (BAY-1142524, CAP-1002, Carvedilol CR, CTX-101, Omecamtiv Mecarbil and Others), Application (Hospital, Clinic and Others) and Region.



On the basis of geography, the market of Left Ventricular Dysfunction Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Drug Type, the sub-segment i.e. Prescription Only will boost the Left Ventricular Dysfunction Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Users, the sub-segment i.e. Kids will boost the Left Ventricular Dysfunction Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
Rising Occurrence Of Heart Failure Among The Elderly Population, Unhealthy Lifestyle and Increasing investment in Research & Development

Challenges:
Lack of Skilled Professionals in Healthcare Sector

Restraints:
Long Waiting Clinical Trials of Drugs and Unavailability of Left Ventricular Dysfunction Drug in Rural Areas

Opportunities:
Number of Pipelined Drugs and Ongoing Clinical Trials for Left Ventricular Dysfunction Drug and Increasing Demand from Emerging Countries

Market Leaders and their expansionary development strategies
In January 2023, Glenmark Pharmaceuticals on Tuesday said it has launched sacubitril and valsartan combination tablets in India for treatment of heart failure. The prescription drug has been launched under brand 'Sacu V' and is priced at Rs 19 per tablet for a dose of 50mg (sacubitril 24mg + valsartan 26mg), Rs 35 per tablet for a dose of 100mg (sacubitril 49mg + valsartan 51mg), and Rs 45 per tablet for a dose of 200mg (sacubitril 97mg + valsartan 103 mg), Glenmark said in a regulatory filing.
In September 2022, Bayer launched a novel heart failure drug in India that it has co-developed with Merck at one-fifteenth of the global price at Rs 127 per pill. It’s a one pill a day therapy. and The drug named Verquvo (vericiguat) is the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalisation among worsening heart failure patients


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Left Ventricular Dysfunction Drug Providers, Venture Capitalists and Private Equity Firms, Government Regulatory, Research Organizations and End Users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • BAY-1142524
  • CAP-1002
  • Carvedilol CR
  • CTX-101
  • Omecamtiv Mecarbil
  • Others
By Application
  • Hospital
  • Clinic
  • Others
By Drug Type
  • Prescription Only
  • Over the Counter

By End Users
  • Kids
  • Adults

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Occurrence Of Heart Failure Among The Elderly Population
      • 3.2.2. Unhealthy Lifestyle
      • 3.2.3. Increasing investment in Research & Development
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professionals in Healthcare Sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Left Ventricular Dysfunction Drug, by Type, Application, Drug Type, End Users and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Left Ventricular Dysfunction Drug (Value)
      • 5.2.1. Global Left Ventricular Dysfunction Drug by: Type (Value)
        • 5.2.1.1. BAY-1142524
        • 5.2.1.2. CAP-1002
        • 5.2.1.3. Carvedilol CR
        • 5.2.1.4. CTX-101
        • 5.2.1.5. Omecamtiv Mecarbil
        • 5.2.1.6. Others
      • 5.2.2. Global Left Ventricular Dysfunction Drug by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Others
      • 5.2.3. Global Left Ventricular Dysfunction Drug by: Drug Type (Value)
        • 5.2.3.1. Prescription Only
        • 5.2.3.2. Over the Counter
      • 5.2.4. Global Left Ventricular Dysfunction Drug by: End Users (Value)
        • 5.2.4.1. Kids
        • 5.2.4.2. Adults
      • 5.2.5. Global Left Ventricular Dysfunction Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Left Ventricular Dysfunction Drug (Volume)
      • 5.3.1. Global Left Ventricular Dysfunction Drug by: Type (Volume)
        • 5.3.1.1. BAY-1142524
        • 5.3.1.2. CAP-1002
        • 5.3.1.3. Carvedilol CR
        • 5.3.1.4. CTX-101
        • 5.3.1.5. Omecamtiv Mecarbil
        • 5.3.1.6. Others
      • 5.3.2. Global Left Ventricular Dysfunction Drug by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinic
        • 5.3.2.3. Others
      • 5.3.3. Global Left Ventricular Dysfunction Drug by: Drug Type (Volume)
        • 5.3.3.1. Prescription Only
        • 5.3.3.2. Over the Counter
      • 5.3.4. Global Left Ventricular Dysfunction Drug by: End Users (Volume)
        • 5.3.4.1. Kids
        • 5.3.4.2. Adults
      • 5.3.5. Global Left Ventricular Dysfunction Drug Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Left Ventricular Dysfunction Drug (Price)
      • 5.4.1. Global Left Ventricular Dysfunction Drug by: Type (Price)
  • 6. Left Ventricular Dysfunction Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Innopharmax Inc (Taiwan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mesoblast Ltd (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Quantum Genomics SA (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. TiGenix NV (Belgium)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Armaron Bio Pty Ltd. (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Takeda Pharmaceutical Co Ltd (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Viscofan BioEngineering (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Left Ventricular Dysfunction Drug Sale, by Type, Application, Drug Type, End Users and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Left Ventricular Dysfunction Drug (Value)
      • 7.2.1. Global Left Ventricular Dysfunction Drug by: Type (Value)
        • 7.2.1.1. BAY-1142524
        • 7.2.1.2. CAP-1002
        • 7.2.1.3. Carvedilol CR
        • 7.2.1.4. CTX-101
        • 7.2.1.5. Omecamtiv Mecarbil
        • 7.2.1.6. Others
      • 7.2.2. Global Left Ventricular Dysfunction Drug by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Others
      • 7.2.3. Global Left Ventricular Dysfunction Drug by: Drug Type (Value)
        • 7.2.3.1. Prescription Only
        • 7.2.3.2. Over the Counter
      • 7.2.4. Global Left Ventricular Dysfunction Drug by: End Users (Value)
        • 7.2.4.1. Kids
        • 7.2.4.2. Adults
      • 7.2.5. Global Left Ventricular Dysfunction Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Left Ventricular Dysfunction Drug (Volume)
      • 7.3.1. Global Left Ventricular Dysfunction Drug by: Type (Volume)
        • 7.3.1.1. BAY-1142524
        • 7.3.1.2. CAP-1002
        • 7.3.1.3. Carvedilol CR
        • 7.3.1.4. CTX-101
        • 7.3.1.5. Omecamtiv Mecarbil
        • 7.3.1.6. Others
      • 7.3.2. Global Left Ventricular Dysfunction Drug by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinic
        • 7.3.2.3. Others
      • 7.3.3. Global Left Ventricular Dysfunction Drug by: Drug Type (Volume)
        • 7.3.3.1. Prescription Only
        • 7.3.3.2. Over the Counter
      • 7.3.4. Global Left Ventricular Dysfunction Drug by: End Users (Volume)
        • 7.3.4.1. Kids
        • 7.3.4.2. Adults
      • 7.3.5. Global Left Ventricular Dysfunction Drug Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Left Ventricular Dysfunction Drug (Price)
      • 7.4.1. Global Left Ventricular Dysfunction Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Left Ventricular Dysfunction Drug: by Type(USD Million)
  • Table 2. Left Ventricular Dysfunction Drug BAY-1142524 , by Region USD Million (2018-2023)
  • Table 3. Left Ventricular Dysfunction Drug CAP-1002 , by Region USD Million (2018-2023)
  • Table 4. Left Ventricular Dysfunction Drug Carvedilol CR , by Region USD Million (2018-2023)
  • Table 5. Left Ventricular Dysfunction Drug CTX-101 , by Region USD Million (2018-2023)
  • Table 6. Left Ventricular Dysfunction Drug Omecamtiv Mecarbil , by Region USD Million (2018-2023)
  • Table 7. Left Ventricular Dysfunction Drug Others , by Region USD Million (2018-2023)
  • Table 8. Left Ventricular Dysfunction Drug: by Application(USD Million)
  • Table 9. Left Ventricular Dysfunction Drug Hospital , by Region USD Million (2018-2023)
  • Table 10. Left Ventricular Dysfunction Drug Clinic , by Region USD Million (2018-2023)
  • Table 11. Left Ventricular Dysfunction Drug Others , by Region USD Million (2018-2023)
  • Table 12. Left Ventricular Dysfunction Drug: by Drug Type(USD Million)
  • Table 13. Left Ventricular Dysfunction Drug Prescription Only , by Region USD Million (2018-2023)
  • Table 14. Left Ventricular Dysfunction Drug Over the Counter , by Region USD Million (2018-2023)
  • Table 15. Left Ventricular Dysfunction Drug: by End Users(USD Million)
  • Table 16. Left Ventricular Dysfunction Drug Kids , by Region USD Million (2018-2023)
  • Table 17. Left Ventricular Dysfunction Drug Adults , by Region USD Million (2018-2023)
  • Table 18. South America Left Ventricular Dysfunction Drug, by Country USD Million (2018-2023)
  • Table 19. South America Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 20. South America Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 21. South America Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 22. South America Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 23. Brazil Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 24. Brazil Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 25. Brazil Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 26. Brazil Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 27. Argentina Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 28. Argentina Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 29. Argentina Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 30. Argentina Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 31. Rest of South America Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 34. Rest of South America Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 35. Asia Pacific Left Ventricular Dysfunction Drug, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 38. Asia Pacific Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 39. Asia Pacific Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 40. China Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 41. China Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 42. China Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 43. China Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 44. Japan Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 45. Japan Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 46. Japan Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 47. Japan Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 48. India Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 49. India Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 50. India Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 51. India Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 52. South Korea Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 53. South Korea Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 54. South Korea Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 55. South Korea Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 56. Taiwan Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 57. Taiwan Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 58. Taiwan Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 59. Taiwan Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 60. Australia Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 61. Australia Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 62. Australia Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 63. Australia Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 68. Europe Left Ventricular Dysfunction Drug, by Country USD Million (2018-2023)
  • Table 69. Europe Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 70. Europe Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 71. Europe Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 72. Europe Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 73. Germany Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 74. Germany Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 75. Germany Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 76. Germany Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 77. France Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 78. France Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 79. France Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 80. France Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 81. Italy Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 82. Italy Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 83. Italy Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 84. Italy Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 85. United Kingdom Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 86. United Kingdom Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 87. United Kingdom Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 88. United Kingdom Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 89. Netherlands Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 90. Netherlands Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 91. Netherlands Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 92. Netherlands Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 93. Rest of Europe Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 94. Rest of Europe Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 95. Rest of Europe Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 96. Rest of Europe Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 97. MEA Left Ventricular Dysfunction Drug, by Country USD Million (2018-2023)
  • Table 98. MEA Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 99. MEA Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 100. MEA Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 101. MEA Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 102. Middle East Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 103. Middle East Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 104. Middle East Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 105. Middle East Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 106. Africa Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 107. Africa Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 108. Africa Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 109. Africa Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 110. North America Left Ventricular Dysfunction Drug, by Country USD Million (2018-2023)
  • Table 111. North America Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 112. North America Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 113. North America Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 114. North America Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 115. United States Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 116. United States Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 117. United States Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 118. United States Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 119. Canada Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 120. Canada Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 121. Canada Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 122. Canada Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 123. Mexico Left Ventricular Dysfunction Drug, by Type USD Million (2018-2023)
  • Table 124. Mexico Left Ventricular Dysfunction Drug, by Application USD Million (2018-2023)
  • Table 125. Mexico Left Ventricular Dysfunction Drug, by Drug Type USD Million (2018-2023)
  • Table 126. Mexico Left Ventricular Dysfunction Drug, by End Users USD Million (2018-2023)
  • Table 127. Left Ventricular Dysfunction Drug Sales: by Type(K Tons)
  • Table 128. Left Ventricular Dysfunction Drug Sales BAY-1142524 , by Region K Tons (2018-2023)
  • Table 129. Left Ventricular Dysfunction Drug Sales CAP-1002 , by Region K Tons (2018-2023)
  • Table 130. Left Ventricular Dysfunction Drug Sales Carvedilol CR , by Region K Tons (2018-2023)
  • Table 131. Left Ventricular Dysfunction Drug Sales CTX-101 , by Region K Tons (2018-2023)
  • Table 132. Left Ventricular Dysfunction Drug Sales Omecamtiv Mecarbil , by Region K Tons (2018-2023)
  • Table 133. Left Ventricular Dysfunction Drug Sales Others , by Region K Tons (2018-2023)
  • Table 134. Left Ventricular Dysfunction Drug Sales: by Application(K Tons)
  • Table 135. Left Ventricular Dysfunction Drug Sales Hospital , by Region K Tons (2018-2023)
  • Table 136. Left Ventricular Dysfunction Drug Sales Clinic , by Region K Tons (2018-2023)
  • Table 137. Left Ventricular Dysfunction Drug Sales Others , by Region K Tons (2018-2023)
  • Table 138. Left Ventricular Dysfunction Drug Sales: by Drug Type(K Tons)
  • Table 139. Left Ventricular Dysfunction Drug Sales Prescription Only , by Region K Tons (2018-2023)
  • Table 140. Left Ventricular Dysfunction Drug Sales Over the Counter , by Region K Tons (2018-2023)
  • Table 141. Left Ventricular Dysfunction Drug Sales: by End Users(K Tons)
  • Table 142. Left Ventricular Dysfunction Drug Sales Kids , by Region K Tons (2018-2023)
  • Table 143. Left Ventricular Dysfunction Drug Sales Adults , by Region K Tons (2018-2023)
  • Table 144. South America Left Ventricular Dysfunction Drug Sales, by Country K Tons (2018-2023)
  • Table 145. South America Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 146. South America Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 147. South America Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 148. South America Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 149. Brazil Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 150. Brazil Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 151. Brazil Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 152. Brazil Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 153. Argentina Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 154. Argentina Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 155. Argentina Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 156. Argentina Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 157. Rest of South America Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 158. Rest of South America Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 159. Rest of South America Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 160. Rest of South America Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 161. Asia Pacific Left Ventricular Dysfunction Drug Sales, by Country K Tons (2018-2023)
  • Table 162. Asia Pacific Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 163. Asia Pacific Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 164. Asia Pacific Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 165. Asia Pacific Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 166. China Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 167. China Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 168. China Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 169. China Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 170. Japan Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 171. Japan Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 172. Japan Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 173. Japan Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 174. India Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 175. India Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 176. India Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 177. India Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 178. South Korea Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 179. South Korea Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 180. South Korea Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 181. South Korea Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 182. Taiwan Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 183. Taiwan Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 184. Taiwan Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 185. Taiwan Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 186. Australia Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 187. Australia Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 188. Australia Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 189. Australia Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 190. Rest of Asia-Pacific Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 191. Rest of Asia-Pacific Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 192. Rest of Asia-Pacific Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 193. Rest of Asia-Pacific Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 194. Europe Left Ventricular Dysfunction Drug Sales, by Country K Tons (2018-2023)
  • Table 195. Europe Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 196. Europe Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 197. Europe Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 198. Europe Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 199. Germany Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 200. Germany Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 201. Germany Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 202. Germany Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 203. France Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 204. France Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 205. France Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 206. France Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 207. Italy Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 208. Italy Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 209. Italy Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 210. Italy Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 211. United Kingdom Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 212. United Kingdom Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 213. United Kingdom Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 214. United Kingdom Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 215. Netherlands Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 216. Netherlands Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 217. Netherlands Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 218. Netherlands Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 219. Rest of Europe Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 220. Rest of Europe Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 221. Rest of Europe Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 222. Rest of Europe Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 223. MEA Left Ventricular Dysfunction Drug Sales, by Country K Tons (2018-2023)
  • Table 224. MEA Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 225. MEA Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 226. MEA Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 227. MEA Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 228. Middle East Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 229. Middle East Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 230. Middle East Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 231. Middle East Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 232. Africa Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 233. Africa Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 234. Africa Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 235. Africa Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 236. North America Left Ventricular Dysfunction Drug Sales, by Country K Tons (2018-2023)
  • Table 237. North America Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 238. North America Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 239. North America Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 240. North America Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 241. United States Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 242. United States Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 243. United States Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 244. United States Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 245. Canada Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 246. Canada Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 247. Canada Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 248. Canada Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 249. Mexico Left Ventricular Dysfunction Drug Sales, by Type K Tons (2018-2023)
  • Table 250. Mexico Left Ventricular Dysfunction Drug Sales, by Application K Tons (2018-2023)
  • Table 251. Mexico Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2018-2023)
  • Table 252. Mexico Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2018-2023)
  • Table 253. Left Ventricular Dysfunction Drug: by Type(USD/Units)
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Left Ventricular Dysfunction Drug: by Type(USD Million)
  • Table 265. Left Ventricular Dysfunction Drug BAY-1142524 , by Region USD Million (2025-2030)
  • Table 266. Left Ventricular Dysfunction Drug CAP-1002 , by Region USD Million (2025-2030)
  • Table 267. Left Ventricular Dysfunction Drug Carvedilol CR , by Region USD Million (2025-2030)
  • Table 268. Left Ventricular Dysfunction Drug CTX-101 , by Region USD Million (2025-2030)
  • Table 269. Left Ventricular Dysfunction Drug Omecamtiv Mecarbil , by Region USD Million (2025-2030)
  • Table 270. Left Ventricular Dysfunction Drug Others , by Region USD Million (2025-2030)
  • Table 271. Left Ventricular Dysfunction Drug: by Application(USD Million)
  • Table 272. Left Ventricular Dysfunction Drug Hospital , by Region USD Million (2025-2030)
  • Table 273. Left Ventricular Dysfunction Drug Clinic , by Region USD Million (2025-2030)
  • Table 274. Left Ventricular Dysfunction Drug Others , by Region USD Million (2025-2030)
  • Table 275. Left Ventricular Dysfunction Drug: by Drug Type(USD Million)
  • Table 276. Left Ventricular Dysfunction Drug Prescription Only , by Region USD Million (2025-2030)
  • Table 277. Left Ventricular Dysfunction Drug Over the Counter , by Region USD Million (2025-2030)
  • Table 278. Left Ventricular Dysfunction Drug: by End Users(USD Million)
  • Table 279. Left Ventricular Dysfunction Drug Kids , by Region USD Million (2025-2030)
  • Table 280. Left Ventricular Dysfunction Drug Adults , by Region USD Million (2025-2030)
  • Table 281. South America Left Ventricular Dysfunction Drug, by Country USD Million (2025-2030)
  • Table 282. South America Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 283. South America Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 284. South America Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 285. South America Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 286. Brazil Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 287. Brazil Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 288. Brazil Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 289. Brazil Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 290. Argentina Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 291. Argentina Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 292. Argentina Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 293. Argentina Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 294. Rest of South America Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 295. Rest of South America Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 296. Rest of South America Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 297. Rest of South America Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 298. Asia Pacific Left Ventricular Dysfunction Drug, by Country USD Million (2025-2030)
  • Table 299. Asia Pacific Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 300. Asia Pacific Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 301. Asia Pacific Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 302. Asia Pacific Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 303. China Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 304. China Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 305. China Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 306. China Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 307. Japan Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 308. Japan Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 309. Japan Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 310. Japan Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 311. India Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 312. India Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 313. India Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 314. India Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 315. South Korea Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 316. South Korea Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 317. South Korea Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 318. South Korea Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 319. Taiwan Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 320. Taiwan Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 321. Taiwan Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 322. Taiwan Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 323. Australia Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 324. Australia Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 325. Australia Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 326. Australia Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 327. Rest of Asia-Pacific Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 328. Rest of Asia-Pacific Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 329. Rest of Asia-Pacific Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 330. Rest of Asia-Pacific Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 331. Europe Left Ventricular Dysfunction Drug, by Country USD Million (2025-2030)
  • Table 332. Europe Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 333. Europe Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 334. Europe Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 335. Europe Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 336. Germany Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 337. Germany Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 338. Germany Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 339. Germany Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 340. France Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 341. France Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 342. France Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 343. France Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 344. Italy Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 345. Italy Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 346. Italy Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 347. Italy Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 348. United Kingdom Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 349. United Kingdom Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 350. United Kingdom Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 351. United Kingdom Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 352. Netherlands Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 353. Netherlands Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 354. Netherlands Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 355. Netherlands Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 356. Rest of Europe Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 357. Rest of Europe Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 358. Rest of Europe Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 359. Rest of Europe Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 360. MEA Left Ventricular Dysfunction Drug, by Country USD Million (2025-2030)
  • Table 361. MEA Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 362. MEA Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 363. MEA Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 364. MEA Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 365. Middle East Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 366. Middle East Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 367. Middle East Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 368. Middle East Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 369. Africa Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 370. Africa Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 371. Africa Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 372. Africa Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 373. North America Left Ventricular Dysfunction Drug, by Country USD Million (2025-2030)
  • Table 374. North America Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 375. North America Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 376. North America Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 377. North America Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 378. United States Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 379. United States Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 380. United States Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 381. United States Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 382. Canada Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 383. Canada Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 384. Canada Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 385. Canada Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 386. Mexico Left Ventricular Dysfunction Drug, by Type USD Million (2025-2030)
  • Table 387. Mexico Left Ventricular Dysfunction Drug, by Application USD Million (2025-2030)
  • Table 388. Mexico Left Ventricular Dysfunction Drug, by Drug Type USD Million (2025-2030)
  • Table 389. Mexico Left Ventricular Dysfunction Drug, by End Users USD Million (2025-2030)
  • Table 390. Left Ventricular Dysfunction Drug Sales: by Type(K Tons)
  • Table 391. Left Ventricular Dysfunction Drug Sales BAY-1142524 , by Region K Tons (2025-2030)
  • Table 392. Left Ventricular Dysfunction Drug Sales CAP-1002 , by Region K Tons (2025-2030)
  • Table 393. Left Ventricular Dysfunction Drug Sales Carvedilol CR , by Region K Tons (2025-2030)
  • Table 394. Left Ventricular Dysfunction Drug Sales CTX-101 , by Region K Tons (2025-2030)
  • Table 395. Left Ventricular Dysfunction Drug Sales Omecamtiv Mecarbil , by Region K Tons (2025-2030)
  • Table 396. Left Ventricular Dysfunction Drug Sales Others , by Region K Tons (2025-2030)
  • Table 397. Left Ventricular Dysfunction Drug Sales: by Application(K Tons)
  • Table 398. Left Ventricular Dysfunction Drug Sales Hospital , by Region K Tons (2025-2030)
  • Table 399. Left Ventricular Dysfunction Drug Sales Clinic , by Region K Tons (2025-2030)
  • Table 400. Left Ventricular Dysfunction Drug Sales Others , by Region K Tons (2025-2030)
  • Table 401. Left Ventricular Dysfunction Drug Sales: by Drug Type(K Tons)
  • Table 402. Left Ventricular Dysfunction Drug Sales Prescription Only , by Region K Tons (2025-2030)
  • Table 403. Left Ventricular Dysfunction Drug Sales Over the Counter , by Region K Tons (2025-2030)
  • Table 404. Left Ventricular Dysfunction Drug Sales: by End Users(K Tons)
  • Table 405. Left Ventricular Dysfunction Drug Sales Kids , by Region K Tons (2025-2030)
  • Table 406. Left Ventricular Dysfunction Drug Sales Adults , by Region K Tons (2025-2030)
  • Table 407. South America Left Ventricular Dysfunction Drug Sales, by Country K Tons (2025-2030)
  • Table 408. South America Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 409. South America Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 410. South America Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 411. South America Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 412. Brazil Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 413. Brazil Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 414. Brazil Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 415. Brazil Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 416. Argentina Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 417. Argentina Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 418. Argentina Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 419. Argentina Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 420. Rest of South America Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 421. Rest of South America Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 422. Rest of South America Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 423. Rest of South America Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 424. Asia Pacific Left Ventricular Dysfunction Drug Sales, by Country K Tons (2025-2030)
  • Table 425. Asia Pacific Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 426. Asia Pacific Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 427. Asia Pacific Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 428. Asia Pacific Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 429. China Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 430. China Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 431. China Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 432. China Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 433. Japan Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 434. Japan Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 435. Japan Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 436. Japan Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 437. India Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 438. India Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 439. India Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 440. India Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 441. South Korea Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 442. South Korea Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 443. South Korea Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 444. South Korea Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 445. Taiwan Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 446. Taiwan Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 447. Taiwan Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 448. Taiwan Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 449. Australia Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 450. Australia Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 451. Australia Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 452. Australia Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 453. Rest of Asia-Pacific Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 454. Rest of Asia-Pacific Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 455. Rest of Asia-Pacific Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 456. Rest of Asia-Pacific Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 457. Europe Left Ventricular Dysfunction Drug Sales, by Country K Tons (2025-2030)
  • Table 458. Europe Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 459. Europe Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 460. Europe Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 461. Europe Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 462. Germany Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 463. Germany Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 464. Germany Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 465. Germany Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 466. France Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 467. France Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 468. France Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 469. France Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 470. Italy Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 471. Italy Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 472. Italy Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 473. Italy Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 474. United Kingdom Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 475. United Kingdom Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 476. United Kingdom Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 477. United Kingdom Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 478. Netherlands Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 479. Netherlands Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 480. Netherlands Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 481. Netherlands Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 482. Rest of Europe Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 483. Rest of Europe Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 484. Rest of Europe Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 485. Rest of Europe Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 486. MEA Left Ventricular Dysfunction Drug Sales, by Country K Tons (2025-2030)
  • Table 487. MEA Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 488. MEA Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 489. MEA Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 490. MEA Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 491. Middle East Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 492. Middle East Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 493. Middle East Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 494. Middle East Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 495. Africa Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 496. Africa Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 497. Africa Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 498. Africa Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 499. North America Left Ventricular Dysfunction Drug Sales, by Country K Tons (2025-2030)
  • Table 500. North America Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 501. North America Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 502. North America Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 503. North America Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 504. United States Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 505. United States Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 506. United States Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 507. United States Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 508. Canada Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 509. Canada Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 510. Canada Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 511. Canada Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 512. Mexico Left Ventricular Dysfunction Drug Sales, by Type K Tons (2025-2030)
  • Table 513. Mexico Left Ventricular Dysfunction Drug Sales, by Application K Tons (2025-2030)
  • Table 514. Mexico Left Ventricular Dysfunction Drug Sales, by Drug Type K Tons (2025-2030)
  • Table 515. Mexico Left Ventricular Dysfunction Drug Sales, by End Users K Tons (2025-2030)
  • Table 516. Left Ventricular Dysfunction Drug: by Type(USD/Units)
  • Table 517. Research Programs/Design for This Report
  • Table 518. Key Data Information from Secondary Sources
  • Table 519. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Left Ventricular Dysfunction Drug: by Type USD Million (2018-2023)
  • Figure 5. Global Left Ventricular Dysfunction Drug: by Application USD Million (2018-2023)
  • Figure 6. Global Left Ventricular Dysfunction Drug: by Drug Type USD Million (2018-2023)
  • Figure 7. Global Left Ventricular Dysfunction Drug: by End Users USD Million (2018-2023)
  • Figure 8. South America Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 9. Asia Pacific Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 10. Europe Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 11. MEA Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 12. North America Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 13. Global Left Ventricular Dysfunction Drug: by Type K Tons (2018-2023)
  • Figure 14. Global Left Ventricular Dysfunction Drug: by Application K Tons (2018-2023)
  • Figure 15. Global Left Ventricular Dysfunction Drug: by Drug Type K Tons (2018-2023)
  • Figure 16. Global Left Ventricular Dysfunction Drug: by End Users K Tons (2018-2023)
  • Figure 17. South America Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 18. Asia Pacific Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 19. Europe Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 20. MEA Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 21. North America Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 22. Global Left Ventricular Dysfunction Drug: by Type USD/Units (2018-2023)
  • Figure 23. Global Left Ventricular Dysfunction Drug share by Players 2023 (%)
  • Figure 24. Global Left Ventricular Dysfunction Drug share by Players (Top 3) 2023(%)
  • Figure 25. Global Left Ventricular Dysfunction Drug share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 29. Innopharmax Inc (Taiwan) Revenue, Net Income and Gross profit
  • Figure 30. Innopharmax Inc (Taiwan) Revenue: by Geography 2023
  • Figure 31. Mesoblast Ltd (Australia) Revenue, Net Income and Gross profit
  • Figure 32. Mesoblast Ltd (Australia) Revenue: by Geography 2023
  • Figure 33. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 35. Quantum Genomics SA (France) Revenue, Net Income and Gross profit
  • Figure 36. Quantum Genomics SA (France) Revenue: by Geography 2023
  • Figure 37. TiGenix NV (Belgium) Revenue, Net Income and Gross profit
  • Figure 38. TiGenix NV (Belgium) Revenue: by Geography 2023
  • Figure 39. Armaron Bio Pty Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 40. Armaron Bio Pty Ltd. (Australia) Revenue: by Geography 2023
  • Figure 41. Takeda Pharmaceutical Co Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 42. Takeda Pharmaceutical Co Ltd (Japan) Revenue: by Geography 2023
  • Figure 43. Viscofan BioEngineering (Germany) Revenue, Net Income and Gross profit
  • Figure 44. Viscofan BioEngineering (Germany) Revenue: by Geography 2023
  • Figure 45. GlaxoSmithKline (Germany) Revenue, Net Income and Gross profit
  • Figure 46. GlaxoSmithKline (Germany) Revenue: by Geography 2023
  • Figure 47. Global Left Ventricular Dysfunction Drug: by Type USD Million (2025-2030)
  • Figure 48. Global Left Ventricular Dysfunction Drug: by Application USD Million (2025-2030)
  • Figure 49. Global Left Ventricular Dysfunction Drug: by Drug Type USD Million (2025-2030)
  • Figure 50. Global Left Ventricular Dysfunction Drug: by End Users USD Million (2025-2030)
  • Figure 51. South America Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 52. Asia Pacific Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 53. Europe Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 54. MEA Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 55. North America Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 56. Global Left Ventricular Dysfunction Drug: by Type K Tons (2025-2030)
  • Figure 57. Global Left Ventricular Dysfunction Drug: by Application K Tons (2025-2030)
  • Figure 58. Global Left Ventricular Dysfunction Drug: by Drug Type K Tons (2025-2030)
  • Figure 59. Global Left Ventricular Dysfunction Drug: by End Users K Tons (2025-2030)
  • Figure 60. South America Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 61. Asia Pacific Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 62. Europe Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 63. MEA Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 64. North America Left Ventricular Dysfunction Drug Share (%), by Country
  • Figure 65. Global Left Ventricular Dysfunction Drug: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Innopharmax Inc (Taiwan)
  • Mesoblast Ltd (Australia)
  • Novartis AG (Switzerland)
  • Quantum Genomics SA (France)
  • TiGenix NV (Belgium)
  • Armaron Bio Pty Ltd. (Australia)
  • Takeda Pharmaceutical Co Ltd (Japan)
  • Viscofan BioEngineering (Germany)
  • GlaxoSmithKline (Germany)
Select User Access Type

Key Highlights of Report


Apr 2024 210 Pages 57 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Left Ventricular Dysfunction Drug Market Quantitative research analysis
Global Left Ventricular Dysfunction Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bayer AG (Germany), Innopharmax Inc (Taiwan), Mesoblast Ltd (Australia), Novartis AG (Switzerland), Quantum Genomics SA (France), TiGenix NV (Belgium), Armaron Bio Pty Ltd. (Australia), Takeda Pharmaceutical Co Ltd (Japan), Viscofan BioEngineering (Germany) and GlaxoSmithKline (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Left Ventricular Dysfunction Drug Market during projected period 2023-2030.
The Left Ventricular Dysfunction Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Left Ventricular Dysfunction Drug Market Report?

Have a Query? Click Here

Other Related Reports

Animal Parasiticides - Comprehensive Study by Type (Endoparasiticides (Oral, Injectables), Ectoparasiticides (Sprays, Pour On, Spot On), Endectocides), Application (Agriculture, Horticulture), Form (...
$ 3350
Guillain-Barre Syndrome Drugs Comprehensive Study by Type (Coversin, Immune Globulin, Others), Application (Clinic, Hospital, Others), Forms (Tablets, Injection), Distribution Channel (Hospital Pharm...
$ 3350
Burkholderia Pseudomallei Infections Drug Comprehensive Study by Type (Cholinesterase inhibitors, Memantine), Application (Reduce Fever, Improves Breathing Conditions, Others), Distribution Channel (...
$ 3650
Pharmacovigilance Software Comprehensive Study by End users (Pharma and Biotech Companies, Contract Research Organizations, Business Process Outsourcing Firms, Other), Software (Oracle Argus Safety, ...
$ 4000
Hyperpigmentation Treatment Comprehensive Study by Disease Type (Melasma, Solar lentigines, Melanoma, Precursors, Vitiligo), Distribution Channel (Beauty Stores, Drug Stores, Dermatology Clinics, Aes...
$ 3800
Digital Diabetes Management Comprehensive Study by Type (Devices, Digital Diabetes Apps, Data Management Software and Platforms), Device Type (Wearable Devices, Handheld Devices), End User (Self/Hom...
$ 3450